市場調查報告書
商品編碼
994770

前臨床CRO(臨床研究委外機構)的全球市場

Preclinical Contract Research Organizations

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球前臨床CRO(臨床研究委外機構)的市場規模,預計在分析期間(2020年∼2027年)將以6.9%的年複合成長率增長,從2020年的43億美元,到2027年達到69億美元。

本報告所分析的市場區隔之一的毒性實驗部門,在分析期間中預計將以6.7%的年複合成長率增長,達到43億美元。

本報告提供全球前臨床CRO(臨床研究委外機構)市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Envigo Corporation
  • Eurofins Scientific
  • ICON Plc
  • Laboratory Corporation of America, Inc.
  • Medpace, Inc.
  • MPI research
  • PARAXEL International Corporation
  • Pharmaceutical Product Development (PPD), LLC
  • PRA Health Sciences, Inc.
  • Wuxi AppTec

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:35公司
目錄
Product Code: MCP22616

Abstract:

Global Preclinical Contract Research Organizations Market to Reach $6.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Preclinical Contract Research Organizations estimated at US$4.3 Billion in the year 2020, is projected to reach a revised size of US$6.9 Billion by 2027, growing at a CAGR of 6.9% over the analysis period 2020-2027. Toxicology Testing, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$4.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bioanalysis & DMPK Studies segment is readjusted to a revised 7.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 6.4% CAGR

The Preclinical Contract Research Organizations market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2027 trailing a CAGR of 6.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Other Services Segment to Record 6.3% CAGR

In the global Other Services segment, USA, Canada, Japan, China and Europe will drive the 6.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$524.8 Million in the year 2020 will reach a projected size of US$807.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$792 Million by the year 2027.

Select Competitors (Total 35 Featured) -

  • Envigo Corporation
  • Eurofins Scientific
  • ICON Plc
  • Laboratory Corporation of America, Inc.
  • Medpace, Inc.
  • MPI research
  • PARAXEL International Corporation
  • Pharmaceutical Product Development (PPD), LLC
  • PRA Health Sciences, Inc.
  • Wuxi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Preclinical Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Preclinical Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Preclinical Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Bioanalysis & DMPK Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Bioanalysis & DMPK Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Bioanalysis & DMPK Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Government & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Government & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Government & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 25: USA Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 28: Canada Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 31: Canada Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 34: Japan Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 37: Japan Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 40: China Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 43: China Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 46: Europe Current & Future Analysis for Preclinical Contract Research Organizations by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Preclinical Contract Research Organizations by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Preclinical Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 55: France Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 58: France Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 61: Germany Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 64: Germany Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 67: Italy Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 70: Italy Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 73: UK Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 76: UK Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 79: Rest of Europe Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Europe Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Europe 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 82: Rest of Europe Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 85: Asia-Pacific Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Asia-Pacific Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Asia-Pacific 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 88: Asia-Pacific Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 91: Rest of World Current & Future Analysis for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of World Historic Review for Preclinical Contract Research Organizations by Service - Toxicology Testing, Bioanalysis & DMPK Studies and Other Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of World 15-Year Perspective for Preclinical Contract Research Organizations by Service - Percentage Breakdown of Value Sales for Toxicology Testing, Bioanalysis & DMPK Studies and Other Services for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of World Current & Future Analysis for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Preclinical Contract Research Organizations by End-Use - Biopharma Companies, Government & Academic Institutes and Medical Device Companies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Preclinical Contract Research Organizations by End-Use - Percentage Breakdown of Value Sales for Biopharma Companies, Government & Academic Institutes and Medical Device Companies for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 35